Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series.
J Cutan Pathol
; 47(8): 742-746, 2020 Aug.
Article
en En
| MEDLINE
| ID: mdl-32196722
ABSTRACT
Checkpoint inhibitors have been revolutionary in the treatment of metastatic melanoma, non-small-cell lung cancer, and renal cell carcinoma. By restricting negative feedback of T-cells, checkpoint inhibitors allow the immune system to identify and destroy malignant cells. This enhanced immune response is efficacious in the treatment of the aforementioned malignancies; however, it may lead to immune-related adverse events. Bullous pemphigoid (BP) is a well-documented cutaneous adverse reaction of checkpoint inhibitors, with a majority of cases reporting an eosinophil-predominant or mixed inflammatory infiltrate. We report two cases of neutrophil-predominant BP presenting in patients on checkpoint inhibitors.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Piel
/
Penfigoide Ampolloso
/
Inhibidores de Puntos de Control Inmunológico
/
Melanoma
/
Neutrófilos
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Año:
2020
Tipo del documento:
Article